Schroder Investment Management Group Acquires 20,204 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Schroder Investment Management Group boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 163,896 shares of the company’s stock after acquiring an additional 20,204 shares during the quarter. Schroder Investment Management Group owned 0.25% of Kymera Therapeutics worth $6,444,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of KYMR. Blue Trust Inc. boosted its stake in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the period. KBC Group NV grew its stake in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares in the last quarter. Quarry LP bought a new position in Kymera Therapeutics in the 3rd quarter worth about $95,000. KLP Kapitalforvaltning AS bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $310,000. Finally, Thrivent Financial for Lutherans bought a new stake in shares of Kymera Therapeutics during the third quarter valued at approximately $313,000.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several research reports. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Stephens restated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target for the company. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. Finally, BTIG Research initiated coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price for the company. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,788 shares of company stock worth $455,202. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Down 6.8 %

KYMR stock opened at $22.07 on Friday. The stock has a market capitalization of $1.43 billion, a PE ratio of -9.43 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52 week low of $21.40 and a 52 week high of $53.27. The firm has a 50 day moving average of $34.02 and a 200 day moving average of $41.07.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.